Knollwood Investment Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

Knollwood Investment Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.48M	Hold	4,988	–	–	0.22%	86
2026 Q1	$2.23M	Hold	4,988	–	–	0.22%	89
2025 Q4	$2.26M	Hold	4,988	–	–	0.21%	102
2025 Q3	$1.95M	Hold	4,988	–	–	0.18%	125
2025 Q2	$2.22M	Hold	4,988	–	–	0.21%	110
2025 Q1	$2.42M	Hold	4,988	–	–	0.27%	98
2024 Q4	$2.01M	Hold	4,988	–	–	0.21%	118
2024 Q3	$2.32M	Hold	4,988	–	–	0.25%	102
2024 Q2	$2.34M	Buy	4,988 +828	+20%	+$359K	0.26%	91
2024 Q1	$1.74M	Hold	4,160	–	–	0.31%	58
2023 Q4	$1.69M	Buy	+4,160	New	+$1.54M	0.35%	54

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Knollwood Investment Advisory's VRTX Position: Q2 2026 in Review

Knollwood Investment Advisory held its Vertex Pharmaceuticals (VRTX) position steady in Q2 2026 at 4,988 shares worth $2.48M. The position accounts for 0.22% of the portfolio, ranked #86.

Knollwood Investment Advisory first reported a position in VRTX in Q4 2023 and has held it in 11 quarters since. 1,763 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Knollwood Investment Advisory held 4,988 shares of Vertex Pharmaceuticals worth $2.48M as of Q2 2026.
Knollwood Investment Advisory left its Vertex Pharmaceuticals share count unchanged in Q2 2026.
Vertex Pharmaceuticals made up 0.22% of Knollwood Investment Advisory's portfolio in Q2 2026, its #86 holding.
Knollwood Investment Advisory first reported a position in Vertex Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
1,763 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Knollwood Investment Advisory's 13F filing for Q2 2026, filed 13 Aug 2026.